1. Scrip
  2. >>Business
  3. >>Deals

Deal Making: If I Knew Then What I Know Today

 
• By Mike Ward and Lubna Ahmed

David Chiswell, Jane Dancer and Konstantinos Efthymiopoulos shared lessons they have learnt over the years about deal making at this year's 'If I Knew Then What I Know Today' panel at the AngloNordic meeting in London.

AngloNordic Panel 2017
Biotech pioneers discuss deal making lessons learned • Source: Lubna Ahmed

Risks, regrets and missed opportunities were some of the underlying themes of this year's 'If I Knew Then What I Know Today'panel discussion at the 14th AngloNordic meeting in London. Scrip's Mike Ward spoke to Kymab Ltd.'s chair, David Chiswell; F-Star Biotechnology Ltd.'s chief operating officer, Jane Dancer; and Konstantinos Efthymiopoulos, SynAffix BV's chair, about deal making, lessons learnt and what they wish they had done – or indeed hadn't done.

One thing that F-Star's Dancer wished she had wasted less time on, in her early days of deal making, was...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

 
• By Joseph Haas, Lisa Takagi, and Manas Mishra

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

Gateway To Africa: Natco Bids For 35.75% Of Adcock Ingram

 
• By Anju Ghangurde

Natco to buy out Adcock Ingram’s minority shareholders in what’s possibly its biggest M&A investment, opening up substantial opportunities in South Africa and the region. If the offer goes through, it will result in the delisting of Adcock, with Bidvest and Natco co-owning the firm.

Scrip M&A Podcast: Is Biopharma M&A In A Holding Pattern Or A ‘New Normal’

 
• By Joseph Haas

Scrip discusses the latest M&A activity and trends with CEO Shawn Titcomb of Allele Capital and Cheryl Reicin, a partner focused on international life sciences activity at Mintz.

Sanofi Doubles Down On Respiratory Vaccines With Vicebio Buy

 
• By Kevin Grogan

The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.

More from Business

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Gateway To Africa: Natco Bids For 35.75% Of Adcock Ingram

 
• By Anju Ghangurde

Natco to buy out Adcock Ingram’s minority shareholders in what’s possibly its biggest M&A investment, opening up substantial opportunities in South Africa and the region. If the offer goes through, it will result in the delisting of Adcock, with Bidvest and Natco co-owning the firm.

Roche, Following Sarepta, Pauses Elevidys Shipments In Certain Countries

 
• By Mandy Jackson

Roche paused shipments of the Duchenne muscular dystrophy gene therapy in countries that reference US FDA approval of Elevidys after the agency asked Sarepta to pause US shipments; it remains available in Japan and Brazil.